FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to a method of selecting one or more antibodies resistant to degradation. Said method includes steps of: a) taking two or more antibodies, b) each residue Asn and Asp in the Fv domain of the antibody is determined conformational mobility Cα-atom using ensemble of models based on homology, c) each residue of Asn and Asp in the Fv antibody domain is used to determine the size of the amino acid residue adjacent to the Asn or Asp residue from the C-terminal side, d) selecting one or more antibodies in which Cα-atom is conformationally fixed and in which on the C-end side to Asn or Asp adjoins an amino acid residue with a surface area accessible to solvent of 111 Å2 or more, where the conformational mobility is the mean-square deviation (RMSD) of the corresponding Cα-atoms of Asn/Asp residues in an ensemble of models based on homology.
EFFECT: invention enables efficient selection of one or more antibodies resistant to degradation.
1 cl, 8 dwg, 3 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES BINDING IL-4 AND/OR BL-13 AND THEIR APPLICATION | 2008 |
|
RU2488595C2 |
ANTIBODIES BINDING IL-4 AND/OR IL-13, AND THEIR USE | 2015 |
|
RU2721236C2 |
ANTIBODIES BINDING IL-4 AND/OR IL-13, AND USE THEREOF | 2015 |
|
RU2705551C2 |
IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
HUMANIZED IMMUNE BODIES FOR CXCR5, THEIR SECONDARIES, AND THEIR USE | 2008 |
|
RU2571515C2 |
ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
ISOLATED HUMANIZED PROTEIN BINDING TO HUMAN GLYCOPROTEIN VI, ISOLATED ANTIBODY BINDING TO HUMAN GLYCOPROTEIN VI | 2018 |
|
RU2778884C2 |
PROTEIN BOUND WITH HUMAN GLYCOPROTEIN, COMPOSITION, PHARMACEUTICAL COMPOSITION, EXPRESSION VECTOR | 2016 |
|
RU2773819C2 |
HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
Authors
Dates
2020-01-21—Published
2014-09-03—Filed